EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CHOSA Oncology AB (CHOSA) fair value: what the stock is really worth

We calculate from audited financials what CHOSA Oncology AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE

CO Thin data Aug 2, 2026

CHOSA Oncology AB

CHOSA · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.1200 · Strongly overvalued (−82%)
!Quality 20/100
!Loss-making · -123.1% net margin (TTM)
!negative free cash flow
!Trails peers (3/8)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Watch CHOSA Oncology AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 35.50 kr 0.3350 Fair Value kr 0.1200 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.

How to read this chart

60‑month range kr 0.3350 – kr 35.50 · fair‑value band kr 0.0900 – kr 0.1800 · the kr 0.6500 price screens above the kr 0.1200 fair value. Dashed = 300-day average. As of Aug 2, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA.

Show more

Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.

Stock analysis

CHOSA Oncology AB (CHOSA) currently trades at kr 0.6500, while our model-based Fair Value estimate is kr 0.1200, implying the stock looks roughly 441.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: kr 0.0900 (bear) to kr 0.1800 (bull), the price of kr 0.6500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

CHOSA Oncology AB reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2022. Reported net income was −5.6M SEK in FY2025.

Key figures

Market cap 75.5M SEK (≈ $7.7M) · P/S ratio 16.4 · Net margin −123% · Return on equity −34.1% · Return on assets (EBIT) −46.9% · Operating margin −97,950% · Revenue (TTM) 4.6M SEK · Free cash flow −8.6M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −82%, CHOSA screens richer than that median.

Fair Value models

Bear kr 0.0900 Fair Value kr 0.1200 Bull kr 0.1800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.0900 kr 0.1200 kr 0.1800 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.0900 kr 0.1200 kr 0.1800 51

Open the full fair value analysis →

Notify me when CHOSA reaches fair value

Put CHOSA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 27 · Market factors (momentum, volatility) 21

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 20
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 19
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CHOSA screens 442% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare CHOSA Oncology AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 647 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −80% · Bottom 25%
Profitability
Return on assets −23% · Below median
Net margin (TTM) −123% · Bottom 25%
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.48× · Cheapest 25%
P/S (TTM) 1.71× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX $984.39 $917.18 −7%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
CSL Limited CSL A$167.10 A$183.81 +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CHOSA Oncology AB · Fair Value
kr 0.1200 −442%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CHOSA Oncology AB Fair Value". https://www.fairvalue-calculator.com/stock/CHOSA

Frequently asked questions

Is CHOSA Oncology AB (CHOSA) overvalued or undervalued?
As of Aug 2, 2026, our model estimates a fair value of kr 0.1200 versus a price of kr 0.6500, about −82% upside (overvalued).
What is the fair value of CHOSA?
Our model-based fair value for CHOSA Oncology AB is kr 0.1200 (as of Aug 2, 2026), built from audited fundamentals. The current price: kr 0.6500.
What is the quality score of CHOSA?
CHOSA Oncology AB has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHOSA Oncology AB (CHOSA)?
Our model-based price target is the fair value of kr 0.1200 (as of Aug 2, 2026) from 1 valuation models. Cautious scenario kr 0.0900, optimistic scenario kr 0.1800. It is a calculation from audited fundamentals, not an analyst target.
What is the CHOSA Oncology AB stock forecast for 2026?
Our models put fair value at kr 0.1200, about −82% upside versus a price of kr 0.6500 (overvalued). Cautious scenario kr 0.0900, optimistic scenario kr 0.1800. The calculation is refreshed regularly with new filings.
What is the revenue of CHOSA Oncology AB (CHOSA)?
CHOSA Oncology AB reported trailing-twelve-month revenue of about 4.6M SEK (latest available figure, as of Aug 2, 2026).
What is the intrinsic value of CHOSA Oncology AB (CHOSA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHOSA Oncology AB it is kr 0.1200 per share (as of Aug 2, 2026), against a price of kr 0.6500. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CHOSA Oncology AB stock overvalued or undervalued in 2026?
As of Aug 2, 2026, CHOSA trades above its calculated fair value: price kr 0.6500, fair value kr 0.1200, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHOSA?
No. The price is what the market pays today (kr 0.6500); the fair value is what the company's own numbers justify (kr 0.1200). For CHOSA Oncology AB the two are kr 0.5300 per share apart. That gap is exactly why we show both numbers side by side.
How much is CHOSA Oncology AB worth?
The market values CHOSA Oncology AB at about 75.5M SEK (market capitalisation, as of Aug 2, 2026). Per share that is kr 0.6500; our models calculate a fair value of kr 0.1200 per share.
What do the bullish and bearish scenarios say about CHOSA?
Our models span a range for CHOSA Oncology AB: cautious scenario kr 0.0900, base kr 0.1200, optimistic kr 0.1800 per share (as of Aug 2, 2026, price kr 0.6500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CHOSA Oncology AB (CHOSA)?
Balance-sheet figures for CHOSA Oncology AB (as of Aug 2, 2026): return on equity −34.1%. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is CHOSA from its 52-week high?
CHOSA Oncology AB trades at kr 0.6500, about 70% below its 52-week high of kr 2.20 and 24% above the low of kr 0.5250 (as of Aug 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1200 is for.
Which stocks are comparable to CHOSA Oncology AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHOSA Oncology AB stock attractive at the current price?
The data as of Aug 2, 2026: price kr 0.6500, calculated fair value kr 0.1200 (−82%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHOSA calculated?
We run CHOSA Oncology AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. CHOSA Oncology AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHOSA Oncology AB (CHOSA)?
The closing price on Sep 15, 2026 was kr 0.6500. Our model-based fair value is kr 0.1200, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHOSA Oncology AB right now?
The price sits above even our optimistic bull case (kr 0.1800). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0900 to kr 0.1800) leaves room in how you read the outcome.

Key figures of CHOSA Oncology AB

How large is the market capitalisation of CHOSA Oncology AB (CHOSA)?
The market capitalisation of CHOSA Oncology AB is 75.5M SEK (≈ $7.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CHOSA Oncology AB (CHOSA)?
The price-to-sales ratio of CHOSA Oncology AB is 16.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CHOSA Oncology AB (CHOSA)?
The net margin of CHOSA Oncology AB is −123% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CHOSA Oncology AB (CHOSA)?
The return on equity (ROE) of CHOSA Oncology AB is −34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHOSA Oncology AB (CHOSA)?
On an EBIT basis the return on assets of CHOSA Oncology AB is −46.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHOSA Oncology AB (CHOSA)?
The operating margin of CHOSA Oncology AB is −97,950% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does CHOSA Oncology AB (CHOSA) generate?
The free cash flow of CHOSA Oncology AB is −8.6M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch CHOSA Oncology AB in the live analysis

One click puts CHOSA Oncology AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.